Signal-Transduction Therapy. A Novel Approach to Disease Management
- 1 November 1994
- journal article
- review article
- Published by Wiley in European Journal of Biochemistry
- Vol. 226 (1) , 1-13
- https://doi.org/10.1111/j.1432-1033.1994.tb20020.x
Abstract
In the past decade it has become apparent that many diseases result from aberrations in signaling pathways. These include proliferative diseases such as cancers, atherosclerosis and psoriasis and inflammatory conditions such as sepsis, rheumatoid arthritis and tissue rejection. These findings refocused the research of the medical community to seek new modalities for disease management which essentially consist of designing drugs which intercept cell signaling. In this review, the emerging success in using tyrosine kinase blockers and other signal interceptors, such as protein kinase C blockers, Ras blockers, Ca2+ signaling inhibitors and estrogen antagonists which inhibit growth of cancer cells in vitro and in vivo, will be discussed. These signal interceptors, especially tyrosine-kinase blockers, are also able to block inflammatory responses and the proliferation of vascular smooth muscle cells and psoriatic keratinocytes. The utility of signal interceptors in analyzing signal-transduction pathways is also discussed.Keywords
This publication has 84 references indexed in Scilit:
- Workshop on suramin with emphasis on prostate cancer: Re-evaluation of response criteriaEuropean Journal Of Cancer, 1993
- The use of immunotoxins for cancer therapyEuropean Journal Of Cancer, 1993
- Tamoxifen enhances the cytotoxic effects of the nitrosourea fotemustine. Results on human melanoma cell linesEuropean Journal Of Cancer, 1993
- The tyrosine kinase inhibitor tyrphostin blocks the cellular actions of nerve growth factorBiochemistry, 1993
- Suramin, an Active Drug for Prostate Cancer: Interim Observations in a Phase I TrialJNCI Journal of the National Cancer Institute, 1993
- The pathogenesis of atherosclerosis: a perspective for the 1990sNature, 1993
- Overexpression of the epidermal growth factor receptor in human pancreatic cancer is associated with concomitant increases in the levels of epidermal growth factor and transforming growth factor alpha.Journal of Clinical Investigation, 1992
- Calphostin C (UCN-1028C), a novel microbial compound, is a highly potent and specific inhibitor of protein kinase CBiochemical and Biophysical Research Communications, 1989
- Cellular ras activity and tumor cell proliferationExperimental Cell Research, 1987
- Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodiesCell, 1985